Top 5 Movers and Shakers in the Buzz

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  16 Jan 2026
 

•   ABUS  
   
  +0.74%
•   IBRX  
   
  -0.18%
•   NVX  
   
  -0.87%
•   PRFX  
   
  -2.59%
•   PRSO  
   
  -0.85%

$VERO Venus Concept is today standout performer, surging an eye-popping 452% on volume of 302 million shares, far above its 2.5 million average. The dramatic move comes after Madryn Asset Management disclosed a 91% stake in the company via an amended 13D/A filing. The market clearly reacted to the backing of a large institutional holder, signaling confidence in the strategy and future prospects.

$IBRX ImmunityBio continues its impressive streak, climbing nearly 40% today and marking 11 consecutive days of gains. The rally is fueled by multiple catalysts: a 700% jump in Anktiva product sales, robust preliminary Q4 revenue growth of 431%, and accelerating enrollment in its bladder cancer trial with a BLA submission expected by year-end. Investor optimism is further buoyed by the positioning as a high-growth commercial-stage biotech, where progress in registrational trials can create outsized upside in both institutional and retail interest. The unusual volume of 174 million shares underscores the intensity of market attention.

$PRFX PainReform also caught traders eyes with a 38% jump on volume of 63.5 million shares, well above its 935K average. The surge is linked to the rebranding and strategic expansion into diversified healthcare and AI-driven energy platforms. Such transformation signals a pivot to higher-growth markets, drawing speculative and momentum-driven buying. Retail traders in particular seem drawn to the story of a small-cap company reinventing itself, creating rapid price appreciation in the short term.

$PRSO Peraso gained 17.6% today, boosted by analyst coverage highlighting a strong drug pipeline. With only 1.5 million shares traded versus an average of 324K, the heightened activity reflects renewed market confidence in the potential to deliver breakthroughs. Investors are paying attention to biotech innovation cycles, and this rally underscores how pipeline visibility and credible analyst endorsement can translate quickly into market action.

$TLSA Tiziana Life Sciences climbed 15.9% after announcing an $8–17.6 million registered direct offering. The additional capital provides runway for the lead intranasal therapy candidate and strengthens balance sheet flexibility. The news coupled with strong investor appetite for small-cap biotech offerings created favorable conditions for a pronounced rally, particularly as liquidity allowed aggressive buyers to step in.

$TLN Talen Energy was today notable laggard, falling 11.3% despite recent upside in its shares. Trading volume of 3.27 million, well above its 856K average, suggests profit-taking after an 11.8% prior surge. Analysts point to potential limits in further upside, and investors appear cautious ahead of upcoming earnings revisions, reflecting a shift in market sentiment from enthusiasm to prudence.

$ABUS Arbutus Biopharma dropped 13.6% as the European Patent Office revoked a key lipid nanoparticle patent, EP2279254. Volume surged to 8.5 million shares, far above its 1.27 million average, as investors digested the legal setback and potential implications for partnerships, including ongoing disputes with Moderna. The move highlights how regulatory and patent risk can swiftly pressure biotech valuations.

$SGML Sigma Lithium slumped 13.9%, trading 12.27 million shares versus a 4.48 million average. The decline follows a downgrade to sell and weak technical patterns, which compounded concerns about growth prospects and near-term operational execution. Options activity and market chatter indicate speculative positioning unwinding, intensifying selling pressure.

$NVX NOVONIX fell 16.2% on 3.1 million shares, far above its 1.4 million average, after updating the timing for commencement of mass production of anode material for Panasonic Energy. Investors reacted negatively to the delay, interpreting it as a potential setback to expected revenue growth and production ramp timelines, underscoring how execution risk remains a key driver for battery material plays.

View All Headlines